[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523514":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":18,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":18,"enrollmentInfo":66,"targetDuration":18,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":39,"whyStopped":18,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"cardiac rehabilitation group","EXPERIMENTAL","Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.",[13],"Behavioral: • Cardiac Rehabilitation",{"label":15,"type":16,"description":17,"interventionNames":18},"control group - no intervention","NO_INTERVENTION","Control Group will have baseline 6-minute walk test and CPET testing followed by a repeat 6-minute walk test and CPET test in 12-14 weeks",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"BEHAVIORAL","• Cardiac Rehabilitation",[9],[25],"supervised cardiac rehabilitation sessions",[27],{"name":28,"affiliation":5,"role":29},"Jai Singh, MD","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Dana B Amaro, RN","CONTACT","704-355-4692","Dana.Amaro@atriumhealth.org",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Sanger Heart and Vascular Institute","RECRUITING","Charlotte","North Carolina","28204","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-80.84313,35.22709,{"lat":49,"lon":48},[52,53],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},{"name":28,"role":29,"phone":18,"phoneExt":18,"email":18},{"type":55,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100523514","capacity-cardiac-amyloidosis-and-physical-activity-study-100523514",false,"NCT06096675","CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study","Pilot Study Evaluating Supervised Cardiac Rehabilitation in Patients With Cardiac Amyloidosis","CAPACITY","Inclusion Criteria:\n\n* Age \\> 18\n* New York Heart Association (NYHA) Class I-III Heart Failure\n* Able to Exercise\n* On stable treatment for their cardiac amyloidosis or under active surveillance\n* Life expectancy of at least 6 months\n* Ability to understand and the willingness to sign a written informed consent document in English, and the willingness\u002Fability to comply with the protocol activities\n* Participant must be able and willing to follow the cardiac rehabilitation activities\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks\n* NYHA Class IV Heart Failure\n* Pulmonary disease requiring home oxygen\n* Gait instability or history of prior falls\n* In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.","ALL","18 Years",{"count":67,"type":68},50,"ESTIMATED","INTERVENTIONAL",[71],"NA","Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.",[74],"Cardiac Amyloidosis",[76,77,78],"heart failure","preserved ejection fraction","cardiac rehabilitation","2025-07-25",{"date":81,"type":82},"2025-07-28","ACTUAL",{"date":84,"type":82},"2024-01-22",{"date":86,"type":68},"2027-06",{"name":5,"class":6},1]